Mandeville HC, Bisogno G, Minard-Colin V, Alaggio R, Ben-Arush M, Chargari C, Coppadoro B, Craigie R, Devalck C, Ferman S, Ferrari A, Glosli H, Alvaro RH, Hol M, Mudry P, Orbach D, Albiac MR, Merks JHM, Jenney MEM.Cancer. 2024 Jul 26. doi: 10.1002/cncr.35497. Online ahead of print.PMID: 39058728
This study evaluated the outcomes of children and young people with localised rhabdomyosarcoma affecting different areas including the eye, the genital/ urinary system, or head and neck areas that are not close to the bottom of the skull. These patients either did not have surgery as their first treatment, or if they had surgery still had some disease remaining.
A total of 359 patients were included. For patients having radiotherapy as part of their treatment, we showed that they could safely receive a lower intensity of one of their chemotherapy drugs (ifosfamide or cyclophosphamide), with 93.7% alive at 5 years. For all patients, the chance of being free of rhabdomyosarcoma at 5 years was better for those having radiotherapy; however, their chance of being alive at 5 years was not better. Patients with rhabdomyosarcoma affecting the eye did have a better chance of being alive at 5 years if they had radiotherapy (97.3%) compared to those who did not have radiotherapy (87.1%).
Finally, we reported the outcomes of 60 patients where their tumour was completely removed by surgeons after they had received chemotherapy, with nothing visible at the edges when the tumour was looked at under the microscope. Interestingly we found that the chance of this group of patients being free of rhabdomyosarcoma, or alive, at 5 years was not improved by having additional radiotherapy
A total of 359 patients were included. For patients having radiotherapy as part of their treatment, we showed that they could safely receive a lower intensity of one of their chemotherapy drugs (ifosfamide or cyclophosphamide), with 93.7% alive at 5 years. For all patients, the chance of being free of rhabdomyosarcoma at 5 years was better for those having radiotherapy; however, their chance of being alive at 5 years was not better. Patients with rhabdomyosarcoma affecting the eye did have a better chance of being alive at 5 years if they had radiotherapy (97.3%) compared to those who did not have radiotherapy (87.1%).
Finally, we reported the outcomes of 60 patients where their tumour was completely removed by surgeons after they had received chemotherapy, with nothing visible at the edges when the tumour was looked at under the microscope. Interestingly we found that the chance of this group of patients being free of rhabdomyosarcoma, or alive, at 5 years was not improved by having additional radiotherapy
